[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100053941":3},{"organization":4,"armGroups":7,"interventions":34,"overallOfficials":39,"centralContacts":40,"locations":46,"responsibleParty":225,"collaborators":39,"id":227,"slug":228,"hasResults":229,"nctId":230,"briefTitle":231,"officialTitle":232,"acronym":39,"eligibilityCriteria":233,"healthyVolunteers":229,"sex":234,"minAge":235,"maxAge":39,"enrollmentInfo":236,"targetDuration":39,"studyType":239,"phases":240,"briefSummary":243,"conditions":244,"keywords":39,"overallStatus":246,"whyStopped":39,"lastUpdateSubmitDate":247,"lastUpdatePostDateStruct":248,"startDateStruct":251,"completionDateStruct":252,"leadSponsor":254,"locationsCount":255},{"fullName":5,"class":6},"VelaVigo Bio Inc","INDUSTRY",[8,14,18,22,26,30],{"label":9,"type":10,"description":11,"interventionNames":12},"VBC108 Dose Level 1","EXPERIMENTAL","Phase 1 dose escalation and backfill: VBC108 at Dose Level 1",[13],"Drug: VBC108",{"label":15,"type":10,"description":16,"interventionNames":17},"VBC108 Dose Level 2","Phase 1 dose escalation and backfill: VBC108 at Dose Level 2",[13],{"label":19,"type":10,"description":20,"interventionNames":21},"VBC108 Dose Level 3","Phase 1 dose escalation and backfill: VBC108 at Dose Level 3",[13],{"label":23,"type":10,"description":24,"interventionNames":25},"VBC108 Dose Level 4","Phase 1 dose escalation and backfill: VBC108 at Dose Level 4",[13],{"label":27,"type":10,"description":28,"interventionNames":29},"VBC108 Dose Level 5","Phase 1 dose escalation and backfill: VBC108 at Dose Level 5",[13],{"label":31,"type":10,"description":32,"interventionNames":33},"VBC108 Dose Level recommended Phase 2 dose (RP2D)","Phase 2a expansion cohort: VBC108 at recommended Phase 2 dose (RP2D) across tumor-specific cohorts",[13],[35],{"type":36,"name":37,"description":37,"armGroupLabels":38,"otherNames":39},"DRUG","VBC108",[9,15,19,23,27,31],null,[41],{"name":42,"role":43,"phone":44,"phoneExt":39,"email":45},"Jun Yan","CONTACT","15800359085","jun.yan@VelaVigo.com",[47,65,80,94,109,124,141,156,173,184,199,214],{"facility":48,"status":39,"city":49,"state":50,"zip":51,"country":52,"countryCode":53,"cosmosGeoPoint":54,"geoPoint":59,"contacts":60},"City of Hope Medical Center","Duarte","California","91010","United States","US",{"type":55,"coordinates":56},"Point",[57,58],-117.97729,34.13945,{"lat":58,"lon":57},[61],{"name":62,"role":43,"phone":63,"phoneExt":39,"email":64},"Dani Castillo, MD","6262182123","dacastillo@coh.org",{"facility":66,"status":39,"city":67,"state":68,"zip":69,"country":52,"countryCode":53,"cosmosGeoPoint":70,"geoPoint":74,"contacts":75},"START Midwest, LLC","Grand Rapids","Michigan","49546",{"type":55,"coordinates":71},[72,73],-85.66809,42.96336,{"lat":73,"lon":72},[76],{"name":77,"role":43,"phone":78,"phoneExt":39,"email":79},"Sreenivasa Chandana","16169545554","sreenivasa.chandana@startmidwest.com",{"facility":81,"status":39,"city":82,"state":82,"zip":83,"country":52,"countryCode":53,"cosmosGeoPoint":84,"geoPoint":88,"contacts":89},"Laura and Issac Perlmutter Cancer Center","New York","10016",{"type":55,"coordinates":85},[86,87],-74.00597,40.71427,{"lat":87,"lon":86},[90],{"name":91,"role":43,"phone":92,"phoneExt":39,"email":93},"Paul Oberstein","12123050592","paul.oberstein@nyulangone.org",{"facility":95,"status":39,"city":96,"state":97,"zip":98,"country":52,"countryCode":53,"cosmosGeoPoint":99,"geoPoint":103,"contacts":104},"Next Oncology - Oncology","San Antonio","Texas","78229",{"type":55,"coordinates":100},[101,102],-98.49363,29.42412,{"lat":102,"lon":101},[105],{"name":106,"role":43,"phone":107,"phoneExt":39,"email":108},"David Sommerhalder","2105809500","dsommerhalder@nextoncology.com",{"facility":110,"status":39,"city":111,"state":112,"zip":113,"country":52,"countryCode":53,"cosmosGeoPoint":114,"geoPoint":118,"contacts":119},"NEXT Oncology Virginia","Fairfax","Virginia","22031",{"type":55,"coordinates":115},[116,117],-77.30637,38.84622,{"lat":117,"lon":116},[120],{"name":121,"role":43,"phone":122,"phoneExt":39,"email":123},"Mohamad Salkeni","7032083159","mohamad.salkeni@usoncology.com",{"facility":125,"status":39,"city":126,"state":127,"zip":128,"country":129,"countryCode":130,"cosmosGeoPoint":131,"geoPoint":135,"contacts":136},"GenesisCare North Shore","St Leonards","New South Wales","2065","Australia","AU",{"type":55,"coordinates":132},[133,134],151.19836,-33.82344,{"lat":134,"lon":133},[137],{"name":138,"role":43,"phone":139,"phoneExt":39,"email":140},"Sarah Maloney","610293555611","sarah.maloney@genesiscare.com",{"facility":142,"status":39,"city":143,"state":144,"zip":145,"country":129,"countryCode":130,"cosmosGeoPoint":146,"geoPoint":150,"contacts":151},"One Clinical Research","Perth","Western Australia","6009",{"type":55,"coordinates":147},[148,149],115.8614,-31.95224,{"lat":149,"lon":148},[152],{"name":153,"role":43,"phone":154,"phoneExt":39,"email":155},"Muhammad Adnan Khattak","610452146726","adnan.khattak@health.wa.gov.au",{"facility":157,"status":39,"city":158,"state":159,"zip":160,"country":161,"countryCode":162,"cosmosGeoPoint":163,"geoPoint":167,"contacts":168},"Beijing Cancer Hospital","Beijing","Beijing Municipality","100142","China","CN",{"type":55,"coordinates":164},[165,166],116.39723,39.9075,{"lat":166,"lon":165},[169],{"name":170,"role":43,"phone":171,"phoneExt":39,"email":172},"Lin Shen","86-13911219511","doctorshenlin@sina.cn",{"facility":174,"status":39,"city":158,"state":159,"zip":175,"country":161,"countryCode":162,"cosmosGeoPoint":176,"geoPoint":178,"contacts":179},"Beijing GoBroad Hospital","102200",{"type":55,"coordinates":177},[165,166],{"lat":166,"lon":165},[180],{"name":181,"role":43,"phone":182,"phoneExt":39,"email":183},"Ming Lu","15801292978","qiminglu_mail@126.com",{"facility":185,"status":39,"city":186,"state":187,"zip":188,"country":161,"countryCode":162,"cosmosGeoPoint":189,"geoPoint":193,"contacts":194},"Zhongshan Hospital","Shanghai","Shanghai Municipality","200032",{"type":55,"coordinates":190},[191,192],121.45806,31.22222,{"lat":192,"lon":191},[195],{"name":196,"role":43,"phone":197,"phoneExt":39,"email":198},"Tianshu Liu","86-13681973996","liu.tianshu@zs-hospital.sh.cn",{"facility":200,"status":39,"city":201,"state":202,"zip":203,"country":161,"countryCode":162,"cosmosGeoPoint":204,"geoPoint":208,"contacts":209},"The First Affiliated Hospital, Zhejiang University School of Medicine","Hangzhou","Zhejiang","310009",{"type":55,"coordinates":205},[206,207],120.16142,30.29365,{"lat":207,"lon":206},[210],{"name":211,"role":43,"phone":212,"phoneExt":39,"email":213},"Jian Ruan","86-19883156851","12258276@qq.com",{"facility":215,"status":39,"city":201,"state":202,"zip":216,"country":161,"countryCode":162,"cosmosGeoPoint":217,"geoPoint":219,"contacts":220},"Zhejiang Cancer Hospital","310022",{"type":55,"coordinates":218},[206,207],{"lat":207,"lon":206},[221],{"name":222,"role":43,"phone":223,"phoneExt":39,"email":224},"Jieer Ying","13858195803","hzyingjieer@163.com",{"type":226,"investigatorFullName":39,"investigatorTitle":39,"investigatorAffiliation":39,"oldNameTitle":39,"oldOrganization":39},"SPONSOR","100053941","phase-1-first-in-human-trial-of-vbc108-in-participants-with-advanced-malignant-solid-tumors-100053941",false,"NCT07700160","First-in-Human Trial of VBC108 in Participants With Advanced Malignant Solid Tumors","Phase 1\u002F2a Open-label Clinical Trial Evaluating VBC108, a CLDN18.2 and CDH17-directed Bi-specific Antibody Drug Conjugate, in Participants With Advanced Malignant Solid Tumors","Inclusion Criteria:\n\n1. The participant or the participant's legally acceptable representative is willing and able to provide a written ICF before initiating any trial procedure.\n2. Histologically or cytologically confirmed unresectable advanced\u002Fmetastatic solid tumor .\n3. At least one measurable lesion as assessed by the investigator according to RECIST v1.1 criteria.\n4. Male or female adults (defined as ≥ 18 years of age).\n5. ECOG performance status 0-1.\n6. Life expectancy greater than 12 weeks.\n7. Archived tumor tissue sample available or able to undergo a fresh biopsy collection.\n8. Adequate organ and bone marrow function.\n9. Participants must meet the minimum washout period requirements before the first dose of investigational drug.\n\nExclusion Criteria:\n\n1. Any unresolved toxicity of Grade ≥2 from previous anti-cancer treatment.\n2. Known or suspected brain metastases, or spinal cord compression.\n3. Prior treatment with an ADC targeting CLDN18.2x CDH17 bispecific ADC.\n4. Prior treatment with any ADC carrying a topoisomerase I inhibitor (TOP1i) payload.\n5. Prior treatment with CLDN18.2 targeting CAR-T.","ALL","18 Years",{"count":237,"type":238},230,"ESTIMATED","INTERVENTIONAL",[241,242],"PHASE1","PHASE2","This is a multicenter, open-label, multiple-dose, FIH Phase 1\u002F2a trial. The Phase 1 portion uses Bayesian optimal interval (BOIN) design to escalate and determine the MTD and\u002For RP2D with potential backfill cohorts. The Phase 2a portion consists of dose optimization followed by cohort expansion to confirm safety and tolerability and to further evaluate the efficacy of the selected RP2D in selected solid tumor malignancies for VBC108.",[245],"Advanced Solid Tumors","NOT_YET_RECRUITING","2026-07-07",{"date":249,"type":250},"2026-07-13","ACTUAL",{"date":249,"type":238},{"date":253,"type":238},"2029-09-17",{"name":5,"class":6},12]